IP Library › Granted Patent US 12,257,222
Granted Patent B2
US 12,257,222 · App. 17/746,250 · Granted Mar 25, 2025

Nutritional product

Inventors: Maura O'Donnell (Hightown, GB); Bridget Lambert (Liverpool, GB); Patricia Wallis (Liverpool, GB); Patricia Rutherford (Liverpool, GB); Simon Heales (London, GB); Sean-David Hughes (London, GB); Helen Cross (London, GB); Simon Eaton (London, GB)
Assignees: VITAFLO (INTERNATIONAL) LTD; UCL BUSINESS LTD
A61K31/20A23L33/12A61K31/19A61K31/70A61K38/02A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,257,222
App. No.
17/746,250
Granted
Mar 25, 2025
Kind
B2
Abstract

The present invention generally relates to the field of dietary therapies for treating disorders associated with mitochondrial dysfunction, including epilepsy.

Claims (29)

1. A method for treatment of mitochondrial dysfunction associated with muscle and arising through inherited or acquired mutations in nuclear and/or mitochondrial DNA, the method comprising administering a composition to an individual having the mitochondrial dysfunction, the composition comprising an effective amount of a combination of decanoic acid and octanoic acid in the form of triglycerides having a weight ratio of the decanoic acid to the octanoic acid of at least 2:1.

2. The method according to claim 1 , wherein a dosage of about 5 g/l to 500 g/l of the decanoic acid is administered to the individual per day.

3. The method according to claim 1 , wherein the decanoic acid is greater than 50% of the total weight of fatty acid content of the composition.

4. The method according to claim 1 , wherein the composition is substantially free from any other saturated fatty acid.

5. The method according to claim 1 , wherein the composition is substantially free from mono- and poly-unsaturated fatty acids.

6. The method according to claim 1 , wherein the weight ratio of the decanoic acid to the octanoic acid is at least 3:1.

7. The method according to claim 1 , wherein the weight ratio of the decanoic acid to the octanoic acid is at least 4:1.

8. The method according to claim 1 , wherein the weight ratio of the decanoic acid to the octanoic acid is at least 5:1.

9. The method according to claim 1 , wherein the weight ratio of the decanoic acid to the octanoic acid is at least 6:1.

10. The method according to claim 1 , wherein the weight ratio of the decanoic acid to the octanoic acid is at least 9:1.

11. The method according to claim 1 , wherein the weight ratio of the decanoic acid to the octanoic acid is at least 10:1.

12. The method according to claim 1 , wherein the weight ratio of the decanoic acid to the octanoic acid is at least 20:1.

13. The method according to claim 1 , wherein the decanoic acid is at least 60% of the total weight of fatty acid content of the composition.

14. The method according to claim 1 , wherein the decanoic acid is at least 70% of the total weight of fatty acid content of the composition.

15. The method according to claim 1 , wherein the decanoic acid is at least 80% of the total weight of fatty acid content of the composition.

16. The method according to claim 1 , wherein the decanoic acid is at least 90% of the total weight of fatty acid content.

17. The method according to claim 1 , wherein the composition has an energy density of 2500 to 3100 kJ per 100 g dry mass.

18. The method according to claim 1 , wherein the composition has an energy density of 2540 to 3080 kJ per 100 g dry mass.

19. The method according to claim 1 , wherein the composition has a ketogenic ratio from 2.7:1 to 3.4:1.

20. The method according to claim 1 , wherein the composition comprises the octanoic acid in an amount less than 10 wt. %.

21. The method according to claim 1 , wherein the composition comprises 33-44 g total saturated fatty acids per 100 g lipids.

22. The method according to claim 1 , wherein the composition comprises 30-37 g of the decanoic acid per 100 g lipids.

23. The method according to claim 1 , wherein the composition comprises coconut oil or palm oil as 70-90 wt. % of total lipids.

24. The method according to claim 1 , wherein the composition comprises 5-8.2 g carbohydrates per 100 g dry mass of the composition.

25. The method according to claim 1 , wherein the composition comprises 14.2-16.2 g protein per 100 g dry mass of the composition.

26. The method according to claim 25 , wherein 40-80 wt. % of the protein is alpha-lactalbumin.

27. The method according to claim 1 , wherein the composition comprises 65-72 g lipids per 100 g dry mass of the composition.

28. The method according to claim 1 , wherein the composition is administered to the individual daily for at least six days.

29. The method according to claim 1 , wherein the decanoic acid is at least 99% of the total weight of fatty acid content of the composition.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2024
From: O'DONNELL, MAURA; LAMBERT, BRIDGET; WALLIS, PATRICIA; RUTHERFORD, PATRICIA; HEALES, SIMON; HUGHES, SEAN-DAVID; CROSS, HELEN; EATON, SIMON
To: VITAFLO (INTERNATIONAL) LTD; UCL BUSINESS PLC
Reel/Frame 069113/0371 →
CHANGE OF NAME Recorded Oct 7, 2024
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 069113/0768 →
Priority Claims (1)
GB 1210699 · Jun 15, 2012 · national
Continuity (3)
Continuation 14406957
Provisional Application 61704277 · Sep 21, 2012
Related Publication 20220273602A1 · Sep 1, 2022
References Cited (50)
US 3658555A · Menz et al. · 1972 [cited by applicant]
US 20070135376A1 · Henderson · 2007 [cited by applicant]
US 20080009467A1 · Henderson · 2008 [cited by applicant]
US 20100204498A1 · Inuma et al. · 2010 [cited by applicant]
US 20110200734A1 · Nasaka et al. · 2011 [cited by applicant]
US 20130303616A1 · Williams et al. · 2013 [cited by applicant]
EP 2351491 · 2011 [cited by applicant]
EP 2484358 · 2012 [cited by applicant]
JP 2002536304 · 2002 [cited by applicant]
JP 2003531857 · 2003 [cited by applicant]
JP 2012097038 · 2012 [cited by applicant]
WO WO2010052847 · 2010 [cited by applicant]
WO 2011040342 · 2011 [cited by applicant]
WO 2013186570A1 · 2013 [cited by applicant]
Chang et al. “The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium” Disease Models & Mechanisms, vol. 5, 2012, pp. 115… [cited by applicant]
Chang et al. “Seizure control by ketogenic diet-associated medium chain fatty acids” Neuropharmacology, vol. 69, 2013, pp. 105-114. [cited by applicant]
Nazari et al. “Fatty acid analysis of Iranian junk food, dairy, and bakery products: Special attention to trans-fats” Journal of Research in Medical Sciences, vol. 17, 2012, pp. 952-957. [cited by applicant]
Alonso et al. “Fatty Acid Composition of Caprine Milk: Major, Branched-Chain, and Trans Fatty Acids” Journal of Dairy Science, vol. 82, No. 5, 1999, pp. 878-884. [cited by applicant]
Wlaz et al. “Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice” Neuropharmacology, vol. 62, 2012, pp. 1882-1889. [cited by applicant]
Hattatsu, Brain and Development, vol. 42, Issue No. 2, 2010, pp. 124-129. [cited by applicant]
Jones et al., “Accumulation of 3-Hydroxy-Fatty Acids in the Culture Medium of Long-Chain L-3-Hydroxyacyl CoA Dehydrogenase (LCHAD) and Mitochondrial Trifunctional Protein-Deficient Skin Fibroblasts: Implications for Med… [cited by applicant]
Jones et al., “Effects of Odd-Numbered Medium-Chain Fatty Acids on the Accumulation of Long-Chain 3-Hydroxy-Fatty Acids in Long-Chain L-3-Hydroxyacyl CoA Dehydrogenase and Mitochondrial Trifunctional Protein Deficient S… [cited by applicant]
Fushiki et al., “Swimming Endurance Capacity of Mice is Increased by Chronic Consumption of Medium-Chain Triglycerides”, The Journal of Nutrition, vol. 125, Issue No. 3, 1995, pp. 531-539. [cited by applicant]
Turner et al., “Enhancement of Muscle Mitochondrial Oxidative Capacity and Alterations in Insulin Action are Lipid Species Dependent”, Diabetes, vol. 58, Issue No. 11, 2009, pp. 2547-2554. [cited by applicant]
Japan Patent Office Communication Application No. P2021-050443, Dispatch No. 022610, Dispatch Date Jan. 25, 2022, 9 pages. [cited by applicant]
Gong et al., “Effect of medium-chain caprylic and capric acids on glucose metabolism in mice with diabetes mellitus”, J Chinese PLA Postgrad Med Sch, Feb. 2012, pp. 108-109 and 113, English abstract. [cited by applicant]
“New release of 3 types of ‘Enelprin’ for elderly people who can quickly supply energy”, Nisshin Oillio, May 9, 2012, webpage available at: http://www.nisshin-oillio.com/company/news/archive/2012/20120509_141941.shtml. [cited by applicant]
“Enelrin strawberry taste”, Nisshin Oillio, webpage available at: https://shop.nisshin.oilliogroup.com/products/detail/24121. [cited by applicant]
European Office Action for corresponding European Application No. 13730925.8, mailed Oct. 17, 2018; (4 pages). [cited by applicant]
Rustralian Office Action for corresponding Australian Application No. 2018200433 mailed Sep. 10, 2018, (5 oages). [cited by applicant]
Sills et al. “Role of octanoic and decanoic acids in the control of seizures” Archives of Disease in Childhood, 1986, vol. 61, pp. 1173-1177. [cited by applicant]
Sills et al., Archives of Disease in Childhood, 1986, 61, 1173-1177 (Year: 1986). [cited by applicant]
Neal, et al., Epilepsia, 50(5):1109-1117, 2009 (Year: 2009). [cited by applicant]
P. Chang et al./ Neuropharmacology 69 (2013) 105-114 (Year: 2013). [cited by applicant]
Japanese Office Action—Patent Application No. P2015-516688—dated Feb. 21, 2017—4 pages (English Translation). [cited by applicant]
Japanese Office Action—Patent Application No. P2015-516688—dated Feb. 21, 2017—4 pages. [cited by applicant]
Communication for Application No. 13730925.8 dated Jun. 9, 2022. [cited by applicant]
Likhodii, “Dietary Fat, Ketosis, and Seizure Resistance in Rats on the Ketogenic Diet”, Epilepsia, vol. 41, Issue No. 11, 2000, pp. 1400-1410. [cited by applicant]
Tonin et al., “Long-Chain 3-Hydroxy Fatty Acids Accumulating in LCHAD and MTP Deficiencies Induce Oxidative Stress in Rat Brain”, Neurochemistry International, vol. 56, Issue No. 8, 2010, pp. 930-936. [cited by applicant]
Fisher et al., “Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)”, Epilepsia, vol. 46, Issue No. 4, 2005, pp. 470-… [cited by applicant]
De Deyn et al., “Chemical Models of Epilepsy With Some Reference to Their Applicability in the Development of Anticonvulsants”, Epilepsy Research, vol. 12, Issue No. 2, 1992, pp. 87-110. [cited by applicant]
European Opposition Communication for Application No. 13730925.8-1109 / 2861226 dated Apr. 5, 2024, 16 pages. [cited by applicant]
1 European Office Action for Appl No. 22202824.3-1109 dated Apr. 24, 2024, 8 pages. [cited by applicant]
Nardin Rachel et al., “Mitochondrial Dysfunction and Neuromuscular Disease” John Wiley & Sons, Inc. Muscle Nerve 24: pp. 170-191, 2001. [cited by applicant]
Wanders et al., “The Enzymology of Mitochondrial Fatty Acid Beta-Oxidation and its Application to follow-up Analysis of Positive Neonatal Screening Results”, Journal of Inherited Metabolic Disease, vol. 33, 2010, pp. 47… [cited by applicant]
Lopaschuk et al., “Myocardial Fatty Acid Metabolism in Health and Disease”, Physiological Reviews, vol. 90, 2010, pp. 207-258. [cited by applicant]
Bartlett et al., “Mitochondrial β-oxidation”, European Journal of Biochemistry, vol. 271, 2004, pp. 462-469. [cited by applicant]
European Office Action for Appl No. 13730925.8-1109 dated Jul. 24, 2024, 13 pages. [cited by applicant]
Yu et al., “Metabolic Causes of Epileptic Encephalopathy”, Epilepsy Research and Treatment, vol. 2013, 2013, pp. 1-20. [cited by applicant]
European Office Action for Appl No. 22202824.3-1109/ 4162934 dated Aug. 7, 2024, 4 pages. [cited by applicant]